Literature DB >> 23081827

Characterizing antiprion compounds based on their binding properties to prion proteins: implications as medical chaperones.

Yuji O Kamatari1, Yosuke Hayano, Kei-ichi Yamaguchi, Junji Hosokawa-Muto, Kazuo Kuwata.   

Abstract

A variety of antiprion compounds have been reported that are effective in ex vivo and in vivo treatment experiments. However, the molecular mechanisms for most of these compounds remain unknown. Here we classified antiprion mechanisms into four categories: I, specific conformational stabilization; II, nonspecific stabilization; III, aggregation; and IV, interaction with molecules other than PrP(C). To characterize antiprion compounds based on this classification, we determined their binding affinities to PrP(C) using surface plasmon resonance and their binding sites on PrP(C) using NMR spectroscopy. GN8 and GJP49 bound specifically to the hot spot in PrP(C), and acted as "medical chaperones" to stabilize the native conformation. Thus, mechanisms I was predominant. In contrast, quinacrine and epigallocathechin bound to PrP(C) rather nonspecifically; these may stabilize the PrP(C) conformation nonspecifically including the interference with the intermolecular interaction following mechanism II. Congo red and pentosan polysulfate bound to PrP(C) and caused aggregation and precipitation of PrP(C), thus reducing the effective concentration of prion protein. Thus, mechanism III was appropriate. Finally, CP-60, an edarabone derivative, did not bind to PrP(C). Thus these were classified into mechanism IV. However, their antiprion activities were not confirmed in the GT + FK system, whose details remain to be elucidated. This proposed antiprion mechanisms of diverse antiprion compounds could help to elucidate their antiprion activities and facilitate effective antiprion drug discovery.
Copyright © 2012 The Protein Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23081827      PMCID: PMC3575857          DOI: 10.1002/pro.2180

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  47 in total

1.  New series of antiprion compounds: pyrazolone derivatives have the potent activity of inhibiting protease-resistant prion protein accumulation.

Authors:  Ayako Kimata; Hidehiko Nakagawa; Ryo Ohyama; Tomoko Fukuuchi; Shigeru Ohta; Katsumi Doh-ura; Takayoshi Suzuki; Naoki Miyata
Journal:  J Med Chem       Date:  2007-09-13       Impact factor: 7.446

2.  Variety of antiprion compounds discovered through an in silico screen based on cellular-form prion protein structure: Correlation between antiprion activity and binding affinity.

Authors:  Junji Hosokawa-Muto; Yuji O Kamatari; Hironori K Nakamura; Kazuo Kuwata
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

3.  Regulating the conformation of prion protein through ligand binding.

Authors:  Norifumi Yamamoto; Kazuo Kuwata
Journal:  J Phys Chem B       Date:  2009-10-01       Impact factor: 2.991

4.  Synthesis of GN8 derivatives and evaluation of their antiprion activity in TSE-infected cells.

Authors:  Tsutomu Kimura; Junji Hosokawa-Muto; Yuji O Kamatari; Kazuo Kuwata
Journal:  Bioorg Med Chem Lett       Date:  2011-01-06       Impact factor: 2.823

Review 5.  25 years after HIV discovery: prospects for cure and vaccine.

Authors:  Luc Montagnier
Journal:  Virology       Date:  2010-02-20       Impact factor: 3.616

6.  Structural and mechanistic basis behind the inhibitory interaction of PcTS on alpha-synuclein amyloid fibril formation.

Authors:  Gonzalo R Lamberto; Andrés Binolfi; María L Orcellet; Carlos W Bertoncini; Markus Zweckstetter; Christian Griesinger; Claudio O Fernández
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-30       Impact factor: 11.205

7.  Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases.

Authors:  Yoshio Tsuboi; Katsumi Doh-Ura; Tatsuo Yamada
Journal:  Neuropathology       Date:  2009-10       Impact factor: 1.906

8.  Design, synthesis, and structure-activity relationship of indole-3-glyoxylamide libraries possessing highly potent activity in a cell line model of prion disease.

Authors:  Mark J Thompson; Vinciane Borsenberger; Jennifer C Louth; Katie E Judd; Beining Chen
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

9.  Darwinian evolution of prions in cell culture.

Authors:  Jiali Li; Shawn Browning; Sukhvir P Mahal; Anja M Oelschlegel; Charles Weissmann
Journal:  Science       Date:  2009-12-31       Impact factor: 47.728

10.  Pharmacological chaperone for the structured domain of human prion protein.

Authors:  Andrew J Nicoll; Clare R Trevitt; M Howard Tattum; Emmanuel Risse; Emma Quarterman; Amaurys Avila Ibarra; Connor Wright; Graham S Jackson; Richard B Sessions; Mark Farrow; Jonathan P Waltho; Anthony R Clarke; John Collinge
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-27       Impact factor: 11.205

View more
  19 in total

1.  The crystal structure of an octapeptide repeat of the prion protein in complex with a Fab fragment of the POM2 antibody.

Authors:  Mridula Swayampakula; Pravas Kumar Baral; Adriano Aguzzi; Nat N V Kav; Michael N G James
Journal:  Protein Sci       Date:  2013-05-31       Impact factor: 6.725

2.  Prion 2016 Poster Abstracts.

Authors: 
Journal:  Prion       Date:  2016       Impact factor: 3.931

3.  Quinacrine promotes replication and conformational mutation of chronic wasting disease prions.

Authors:  Jifeng Bian; Hae-Eun Kang; Glenn C Telling
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-07       Impact factor: 11.205

4.  Unfolded and intermediate states of PrP play a key role in the mechanism of action of an antiprion chaperone.

Authors:  Rafayel Petrosyan; Shubhadeep Patra; Negar Rezajooei; Craig R Garen; Michael T Woodside
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-02       Impact factor: 11.205

5.  A Native-like Intermediate Serves as a Branching Point between the Folding and Aggregation Pathways of the Mouse Prion Protein.

Authors:  Ryo P Honda; Ming Xu; Kei-Ichi Yamaguchi; Heinrich Roder; Kazuo Kuwata
Journal:  Structure       Date:  2015-08-06       Impact factor: 5.006

6.  Identifying Anti-prion Chemical Compounds Using a Newly Established Yeast High-Throughput Screening System.

Authors:  Zhiqiang Du; Stephanie Valtierra; Luzivette Robles Cardona; Sara Fernandez Dunne; Chi-Hao Luan; Liming Li
Journal:  Cell Chem Biol       Date:  2019-10-23       Impact factor: 8.116

7.  Anti-prion activity of a panel of aromatic chemical compounds: in vitro and in silico approaches.

Authors:  Natalia C Ferreira; Icaro A Marques; Wesley A Conceição; Bruno Macedo; Clarice S Machado; Alessandra Mascarello; Louise Domeneghini Chiaradia-Delatorre; Rosendo Augusto Yunes; Ricardo José Nunes; Andrew G Hughson; Lynne D Raymond; Pedro G Pascutti; Byron Caughey; Yraima Cordeiro
Journal:  PLoS One       Date:  2014-01-06       Impact factor: 3.240

Review 8.  Successes and challenges in phenotype-based lead discovery for prion diseases.

Authors:  Sina Ghaemmaghami; Miranda Russo; Adam R Renslo
Journal:  J Med Chem       Date:  2014-04-24       Impact factor: 7.446

9.  Discovery of Novel Anti-prion Compounds Using In Silico and In Vitro Approaches.

Authors:  Jae Wook Hyeon; Jiwon Choi; Su Yeon Kim; Rajiv Gandhi Govindaraj; Kyu Jam Hwang; Yeong Seon Lee; Seong Soo A An; Myung Koo Lee; Jong Young Joung; Kyoung Tai No; Jeongmin Lee
Journal:  Sci Rep       Date:  2015-10-09       Impact factor: 4.379

10.  A cationic tetrapyrrole inhibits toxic activities of the cellular prion protein.

Authors:  Tania Massignan; Sara Cimini; Claudia Stincardini; Milica Cerovic; Ilaria Vanni; Saioa R Elezgarai; Jorge Moreno; Matteo Stravalaci; Alessandro Negro; Valeria Sangiovanni; Elena Restelli; Geraldina Riccardi; Marco Gobbi; Joaquín Castilla; Tiziana Borsello; Romolo Nonno; Emiliano Biasini
Journal:  Sci Rep       Date:  2016-03-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.